Chemokine Receptors: Attractive Targets for Drug Discovery

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Annals of the New York Academy of Sciences

• Publication date

  2005-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1196/annals.1361.109PMID 16127005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects

  2005cited by this paper
• CCR1 antagonists for the treatment of autoimmune diseases.

  2004cited by this paper
• FTY720: mechanism of action and potential benefit in organ transplantation.

  2004cited by this paper
• Randomized multicenter trial of natalizumab in acute MS relapses

  2004cited by this paper
• Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells

  2004cited by this paper
• Lymphocyte trafficking across high endothelial venules: dogmas and enigmas

  2004cited by this paper
• I‐TAC/CXCL11 is a natural antagonist for CCR5

  2004cited by this paper
• Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-γ (Mig, CXCL9)

  2004cited by this paper
• A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease

  2004cited by this paper
• Post-onset inhibition of murine arthritis using combined chemokine antagonist therapy.

  2004cited by this paper
• A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2)

  2004cited by this paper
• Chemokines: multiple levels of leukocyte migration control.

  2004cited by this paper
• Adhesion mechanisms regulating the migration of monocytes

  2004cited by this paper
• Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis.

  2004cited by this paper
• Differential Desensitization, Receptor Phosphorylation, β-Arrestin Recruitment, and ERK1/2 Activation by the Two Endogenous Ligands for the CC Chemokine Receptor 7*

  2004cited by this paper
• Unusual Chemokine Receptor Antagonism Involving a Mitogen-Activated Protein Kinase Pathway1

  2004cited by this paper
• Chemokine Receptors and Drug Discovery--SMR meeting. 11 March 2004, Horsham, UK.

  2004cited by this paper
• Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate.

  2004cited by this paper
• Chemokine inhibition--why, when, where, which and how?

  2004cited by this paper
• Eotaxin-3/CCL26 Is a Natural Antagonist for CC Chemokine Receptors 1 and 5

  2004cited by this paper
• Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression

  2004cited by this paper
• Drug discovery and chemokine receptor antagonists: eppur si muove!

  2004cited by this paper
• Regulation of Cockroach Antigen-Induced Allergic Airway Hyperreactivity by the CXCR3 Ligand CXCL91

  2004cited by this paper
• FTY720-Enhanced T Cell Homing Is Dependent on CCR2, CCR5, CCR7, and CXCR4: Evidence for Distinct Chemokine Compartments1

  2004cited by this paper
• CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11

  2003cited by this paper
• A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.

  2003cited by this paper
• Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis

  2003cited by this paper
• Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice: susceptibility in multiple strains.

  2003cited by this paper
• An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4

  2003cited by this paper
• Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes.

  2003cited by this paper
• Development and evaluation of pharmacological agents targeting chemokine receptors.

  2003cited by this paper
• Chemokines and chemokine receptors in rheumatoid arthritis.

  2003cited by this paper
• International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

  2003cited by this paper
• Chemokines in autoimmunity: from pathology to therapeutics.

  2002cited by this paper
• A non‐peptide CCR5 antagonist inhibits collagen‐induced arthritis by modulating T cell migration without affecting anti‐collagen T cell responses

  2002cited by this paper
• New therapeutics that modulate chemokine networks

  2002cited by this paper
• BX-471 Berlex.

  2002cited by this paper
• Chemokines, chemokine receptors and small-molecule antagonists: recent developments.

  2002cited by this paper
• Resident Cell Chemokine Expression Serves as the Major Mechanism for Leukocyte Recruitment During Local Inflammation

  2002cited by this paper
• Design, synthesis, and discovery of a novel CCR1 antagonist.

  2001cited by this paper
• Chemokines in autoimmune disease.

  2001cited by this paper
• The T cell chemokine receptor CCR7 is internalized on stimulation with ELC, but not with SLC

  2001cited by this paper
• The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3*

  2001cited by this paper
• AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-γ Receptor-Deficient Mice1

  2001cited by this paper
• Chemokines and disease

  2001cited by this paper
• Resistance to Experimental Autoimmune Encephalomyelitis in Mice Lacking the Cc Chemokine Receptor (Ccr2)

  2000cited by this paper
• Chemokines: a new classification system and their role in immunity.

  2000cited by this paper
• International union of pharmacology. XXII. Nomenclature for chemokine receptors.

  2000cited by this paper
• Chemokines--chemotactic cytokines that mediate inflammation.

  1998cited by this paper
• Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice.

  1997cited by this paper

• Blocking CCL3-mediated neutrophil recruitment into the brain alleviates immunopathology following severe enterovirus 71 infection

  2024cites this paper
• Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity

  2023cites this paper
• Introduction on therapeutic opportunities for autoimmunity

  2022cites this paper
• The progress of chemokines and chemokine receptors in autism spectrum disorders.

  2021cites this paper
• Discovery and optimization of pyrazole amides as antagonists of CCR1.

  2019cites this paper
• Identification of novel azaindazole CCR1 antagonist clinical candidates.

  2019cites this paper
• Agarose Spot as a Comparative Method for in situ Analysis of Simultaneous Chemotactic Responses to Multiple Chemokines

  2017cites this paper
• Grapefruit-Derived Nanovectors Use an Activated Leukocyte Trafficking Pathway to Deliver Therapeutic Agents to Inflammatory Tumor Sites.

  2015cites this paper
• Chemokines in Wound Healing and as Potential Therapeutic Targets for Reducing Cutaneous Scarring

  2015cites this paper
• Analysis of patents on anti-rheumatoid arthritis therapies issued in China

  2015cites this paper
• Immune Cell Trafficking in the Central Nervous System

  2014cites this paper
• Immune Cell Traffi cking in the Central Nervous System

  2014cites this paper
• Anti‐Inflammatory and Immunomodulatory Drugs

  2013cites this paper
• Novel Anti‐Inflammatory Treatments for Asthma and COPD

  2012cites this paper
• Therapeutic potential of CCR1 antagonists for multiple myeloma.

  2011cites this paper
• CCR1 as a target for multiple myeloma

  2011cites this paper
• Bioinformatics for immunomics

  2010cites this paper
• Role of pro-inflammatory and homeostatic chemokines in diabetic nephropathy

  2010cites this paper
• Understanding autoimmune disease: new targets for drug discovery.

  2009cites this paper
• Chapter 8. Activation mechanisms of chemokine receptors.

  2009cites this paper
• The role of chemokines in acute renal allograft rejection and chronic allograft injury.

  2009cites this paper
• The value and association of CC chemokine receptor 7 expression in non-small cell lung cancer with lymph nodes metastasis

  2009cites this paper
• Computational Vaccinology

  2009cites this paper
• Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3.

  2008cites this paper
• The development of novel therapies for rheumatoid arthritis

  2008cites this paper
• [The value and association of CCR7 expression in NSCLC with lymph node metastasis.].

  2008cites this paper
• Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3.

  2008cites this paper
• A new protocol for high-yield purification of recombinant human CXCL8((3-72))K11R/G31P expressed in Escherichia coli.

  2008cites this paper
• Human articular chondrocytes express Chemerin receptor, ChemR23, which conveys inflammatory signalling

  2008cites this paper
• MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

  2007cites this paper
• The Chemokine System and Arthritis

  2007cites this paper
• The chemokine receptors

  2007cites this paper
• Harnessing bioinformatics to discover new vaccines.

  2007cites this paper
• CCL2‐independent role of CCR2 in immune responses against Leishmania major

  2007cites this paper
• CCR4-Expressing T Cell Tumors Can Be Specifically Controlled via Delivery of Toxins to Chemokine Receptors1

  2007cites this paper
• Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases.

  2006cites this paper
• CC chemokine receptor (CCR)-2 prevents arthritis development following infection by Mycobacterium avium

  2006cites this paper
• Purification and characterization of a high specificity polyclonal antibody to the adenomatous polyposis coli tumour suppressor protein.

  2006cites this paper
• Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo

  2006cites this paper